Sort
51,593 grants matching “hepatitis”
2/3 COMpAAAS Tripartite: ART-CC, KP, and VA
$607,613Michael J Silverberg · Kaiser Foundation Research Institute · U01 · FY2017 · AA
CETP and HDL Function in Cardiovascular Diseases
$607,612Yuqing E Chen · University Of Michigan At Ann Arbor · R01 · FY2014 · HL
Designing T-cell Based HIV Vaccines using Peptide-MHC Surface Morphology
$607,604Ha Youn Lee · University Of Southern California · R01 · FY2014 · AI
Mechanisms of Altered Hepatic Transport: Impact on Drug Therapy
$607,595Kim L Brouwer · Univ Of North Carolina Chapel Hill · R35 · FY2024 · GM
Randomized Trial of Diet in GDM: Metabolic Consequences to Mother and Offspring
$607,560Teri L Hernandez · University Of Colorado Denver · R01 · FY2016 · DK
Administrative Core
$607,534Craig J McClain · University Of Louisville · P20 · FY2021 · GM
Therapeutic Approaches to Dysregulated HDL Metabolism
$607,496Henry J. Pownall · Baylor College Of Medicine · R01 · FY2009 · HL
Candidate Genes Affecting Adolescent Metabolic Syndrome
$607,429Ahmed H Kissebah · Medical College Of Wisconsin · R01 · FY2010 · DK
Therapeutic Strategies and Molecular Correlates in Aggressive B-cell Lymphomas
$607,425Wyndham H Wilson · Division Of Clinical Sciences - Nci · ZIA · FY2022 · CA
Large Data Spatiotemporal Modeling of Optimal Combinations of Interventions to Reduce Opioid Harm in the United States
$607,413Magdalena Cerda · New York University School Of Medicine · R01 · FY2025 · DA
Mechanisms of Altered Hepatic Transport: Impact on Drug Therapy
$607,396Kim L Brouwer · Univ Of North Carolina Chapel Hill · R35 · FY2025 · GM
Social networks and HIV risk among rural drug users
$607,327Jennifer R Havens · University Of Kentucky · R01 · FY2009 · DA
Lipogenesis, lipoprotein flux & CVD risk: role of meal composition & frequency
$607,272Jean-Marc Schwarz · Touro University Of California · R01 · FY2015 · HL
Development of a 3D multi-modal perfusion-thermal electrode system
$607,252Xiaoming Yang · University Of Washington · R01 · FY2021 · EB
Alpha-Particle Emitter Radiopharmaceutical Therapy for Liver Cancer
$607,192Jessie Nedrow · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Technology Development Project
$607,152William Nicholas Haining · Massachusetts General Hospital · U19 · FY2010 · AI
Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers
$607,087Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention
$606,805Joshua T Herbeck · University Of Washington · R01 · FY2019 · DA
Nutritional Status In HIV Hispanic Drug Abusers
$606,735Tufts University Boston · R01 · FY2004 · DA
DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs
$606,428Bruce R Schackman · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · DA
Drug tourism to Mexico: Impact of Mexicos new drug law on HIV-HCV-TB in US IDUs
$606,420Richard S Garfein · University Of California, San Diego · R01 · FY2012 · DA
Vitamin E Pharmacokinetics And Biomarkers In Normal And Obese Women
$606,374Mark A Levine · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
CONTRAST-ENHANCED ULTRASOUND EVALUATION OF FOCAL LIVER LESIONS IN PATIENTS WITH CIRRHOSIS OR OTHER RISK FACTORS FOR DEVELOPING HCC
$606,361Andrej Lyshchik · Thomas Jefferson University · R01 · FY2018 · CA
Non-Invasive Radio-Frequency Field Induced Therapy Destruction of Malignant Cells
$606,330Steven Alan Curley · Methodist Hospital Research Institute · U54 · FY2013 · CA
Hepadnavirus Infections and Liver Cancer
$606,190William Mason · Research Inst Of Fox Chase Can Ctr · R01 · FY2006 · AI